LANFRANCHI, CHIARA
LANFRANCHI, CHIARA
Universita' degli Studi di MILANO
A case of severe pulmonary exacerbation in a young patient with cystic fibrosis in the era of CFTR modulators
2024 C. Lanfranchi, C. Rizza, M.C. Russo, I. Borzani, S.A. Angileri, E. Nazzari, G. Alicandro, F. Blasi, V. Daccò
Effects of prolonged proton pump inhibitor treatment on nutritional status and respiratory infection risk in cystic fibrosis: A matched cohort study
2023 L. Zazzeron, G. Alicandro, V. Daccò, C. Lanfranchi, A. Bulfamante, C. Sathya Sciarrabba, F. Corti, C. Colombo
Effects of elexacaftor / tezacaftor / ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes
2023 V. Grancini, A. Gramegna, L. Zazzeron, G. Alicandro, L.L. Porcaro, F. Piedepalumbo, C. Lanfranchi, V. Daccò, E. Orsi, F. Blasi
Safety of mRNA-based vaccines against SARS-CoV-2 in people with cystic fibrosis aged 12 years and over
2022 G. Alicandro, V. Daccó, L. Cariani, M. Contarini, L.C. Morlacchi, C. Rosazza, C.S. Sciarrabba, F. Ferraro, C. Lanfranchi, B.S. Orena, A. Gramegna, F. Blasi, C. Colombo
Immunogenicity of BNT162b2 mRNA-based vaccine against SARS-CoV-2 in people with cystic fibrosis according to disease characteristics and maintenance therapies
2022 G. Alicandro, V. Daccò, L. Cariani, C. Rosazza, C.S. Sciarrabba, F. Ferraro, C. Lanfranchi, P. Medino, D. Girelli, C. Colombo